{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T17:06:03Z","timestamp":1780592763212,"version":"3.54.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:00:00Z","timestamp":1709856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:00:00Z","timestamp":1709856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Familial hypercholesterolemia (FH) is one of the most common inherited diseases characterized by elevated LDL-cholesterol levels, leading to early-onset atherosclerosis. While the association between FH and coronary and carotid artery disease is well-established, its association with peripheral artery disease (PAD) is less robust. This systematic review aims at exploring existing evidence on PAD prevalence and incidence in FH individuals.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A comprehensive search was conducted on MEDLINE and Embase databases, for studies published between January 2013 and December 2023, evaluating prevalence and incidence of PAD in FH patients. Literature reviews, case reports, responses to editors and non-English language articles were excluded.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The initial research provided 53 results. After article screening, 28 articles were fully reviewed and 24 were finally included in the analysis. Among these, 19 reported PAD prevalence, while 5 PAD incidence over a mean follow-up time of 8.7 years. PAD prevalence and incidence ranged from 0.3 to 60% and from 0.5 to 4.2% respectively, probably reflecting the heterogeneity in PAD definition criteria.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This systematic review sheds light on the limited number of studies on PAD in FH patients. Particularly, considering the potential positive effects of newly available lipid-lowering strategies on PAD outcomes, addressing this research gap is pivotal for a more comprehensive understanding of peripheral vascular manifestations in FH patients and for optimal management of this population.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12020-024-03763-x","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T13:01:38Z","timestamp":1709902898000},"page":"122-133","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Peripheral artery disease: an underdiagnosed condition in familial hypercholesterolemia? A systematic review"],"prefix":"10.1007","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8412-5705","authenticated-orcid":false,"given":"Elisa","family":"Acitelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4571-6219","authenticated-orcid":false,"given":"Alexis F.","family":"Guedon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3155-5525","authenticated-orcid":false,"given":"Sara","family":"De Liguori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8887-994X","authenticated-orcid":false,"given":"Antonio","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3117-7488","authenticated-orcid":false,"given":"Marianna","family":"Maranghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,8]]},"reference":[{"key":"3763_CR1","doi-asserted-by":"publisher","unstructured":"EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC), Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Lancet 398, 1713\u20131725 (2021). https:\/\/doi.org\/10.1016\/S0140-6736(21)01122-3","DOI":"10.1016\/S0140-6736(21)01122-3"},{"key":"3763_CR2","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/aje\/kwh236","volume":"160","author":"MA Austin","year":"2004","unstructured":"M.A. Austin, C.M. Hutter, R.L. Zimmern, S.E. Humphries, Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am. J. Epidemiol. 160, 407\u2013420 (2004). https:\/\/doi.org\/10.1093\/aje\/kwh236","journal-title":"Am. J. Epidemiol."},{"key":"3763_CR3","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","volume":"34","author":"BG Nordestgaard","year":"2013","unstructured":"B.G. Nordestgaard, M.J. Chapman, S.E. Humphries, H.N. Ginsberg, L. Masana, O.S. Descamps, O. Wiklund, R.A. Hegele, F.J. Raal, J.C. Defesche, A. Wiegman, R.D. Santos, G.F. Watts, K.G. Parhofer, G.K. Hovingh, P.T. Kovanen, C. Boileau, M. Averna, J. Bor\u00e9n, E. Bruckert, A.L. Catapano, J.A. Kuivenhoven, P. Pajukanta, K. Ray, A.F. Stalenhoef, E. Stroes, M.R. Taskinen, A. Tybj\u00e6rg-Hansen; European Atherosclerosis Society Consensus Panel, Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur. Heart J. 34, 3478\u20133490a (2013). https:\/\/doi.org\/10.1093\/eurheartj\/eht273","journal-title":"Eur. Heart J."},{"key":"3763_CR4","doi-asserted-by":"publisher","first-page":"3956","DOI":"10.1210\/jc.2012-1563","volume":"97","author":"M Benn","year":"2012","unstructured":"M. Benn, G.F. Watts, A. Tybjaerg-Hansen, B.G. Nordestgaard, Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J. Clin. Endocrinol. Metab. 97, 3956\u20133964 (2012). https:\/\/doi.org\/10.1210\/jc.2012-1563","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3763_CR5","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1161\/CIRCULATIONAHA.119.044795","volume":"141","author":"P Hu","year":"2020","unstructured":"P. Hu, K.I. Dharmayat, C.A.T. Stevens, M.T.A. Sharabiani, R.S. Jones, G.F. Watts, J. Genest, K.K. Ray, A.J. Vallejo-Vaz, Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis. Circulation 141, 1742\u20131759 (2020). https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044795","journal-title":"Circulation"},{"key":"3763_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.acvd.2021.11.005","volume":"115","author":"M Hauguel-Moreau","year":"2022","unstructured":"M. Hauguel-Moreau, V. A\u00efdan, H. Hergault, A. Beauchet, M. P\u00e9pin, G. Prati, R. Pilli\u00e8re, M. Ouadahi, L. Josseran, C. Rodon, J.P. Rab\u00e8s, P. Charron, O. Dubourg, Z. Massy, N. Mansencal, Prevalence of familial hypercholesterolaemia in patients presenting with premature acute coronary syndrome. Arch. Cardiovasc Dis. 115, 87\u201395 (2022). https:\/\/doi.org\/10.1016\/j.acvd.2021.11.005","journal-title":"Arch. Cardiovasc Dis."},{"key":"3763_CR7","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.1161\/CIR.0000000000001005","volume":"144","author":"MH Criqui","year":"2021","unstructured":"M.H. Criqui, K. Matsushita, V. Aboyans, C.N. Hess, C.W. Hicks, T.W. Kwan, M.M. McDermott, S. Misra, F. Ujueta; American Heart Association Council on Epidemiology and Prevention; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; Council on Lifestyle and Cardiometabolic Health; Council on Peripheral Vascular Disease; and Stroke Council, Lower Extremity Peripheral Artery Disease: Contemporary Epidemiology, Management Gaps, and Future Directions: A Scientific Statement From the American Heart Association. Circulation 144, e171\u2013e191 (2021). https:\/\/doi.org\/10.1161\/CIR.0000000000001005","journal-title":"Circulation"},{"key":"3763_CR8","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","volume":"76","author":"GA Roth","year":"2020","unstructured":"G.A. Roth, G.A. Mensah, C.O. Johnson, G. Addolorato, E. Ammirati, L.M. Baddour, N.C. Barengo, A.Z. Beaton, E.J. Benjamin, C.P. Benziger, A. Bonny, M. Brauer, M. Brodmann, T.J. Cahill, J. Carapetis, A.L. Catapano, S.S. Chugh, L.T. Cooper, J. Coresh, M. Criqui, N. DeCleene, K.A. Eagle, S. Emmons-Bell, V.L. Feigin, J. Fern\u00e1ndez-Sol\u00e0, G. Fowkes, E. Gakidou, S.M. Grundy, F.J. He, G. Howard, F. Hu, L. Inker, G. Karthikeyan, N. Kassebaum, W. Koroshetz, C. Lavie, D. Lloyd-Jones, H.S. Lu, A. Mirijello, A.M. Temesgen, A. Mokdad, A.E. Moran, P. Muntner, J. Narula, B. Neal, M. Ntsekhe, G. Moraes de Oliveira, C. Otto, M. Owolabi, M. Pratt, S. Rajagopalan, M. Reitsma, A.L.P. Ribeiro, N. Rigotti, A. Rodgers, C. Sable, S. Shakil, K. Sliwa-Hahnle, B. Stark, J. Sundstr\u00f6m, P. Timpel, I.M. Tleyjeh, M. Valgimigli, T. Vos, P.K. Whelton, M. Yacoub, L. Zuhlke, C. Murray, V. Fuster; GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group, Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J. Am. Coll. Cardiol. 76, 2982\u20133021 (2020). https:\/\/doi.org\/10.1016\/j.jacc.2020.11.010","journal-title":"J. Am. Coll. Cardiol."},{"key":"3763_CR9","doi-asserted-by":"publisher","unstructured":"C. Adou, J. Magne, N. Gazere, M. Aouida, L. Chastaingt, V. Aboyans. Global Epidemiology of Lower Extremity Artery Disease in the 21st Century (2000-2021): a Systematic Review and Meta-analysis. Eur. J. Prev. Cardiol. zwad381 (2023). https:\/\/doi.org\/10.1093\/eurjpc\/zwad381","DOI":"10.1093\/eurjpc\/zwad381"},{"key":"3763_CR10","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1161\/CIRCULATIONAHA.118.035432","volume":"138","author":"AW Aday","year":"2018","unstructured":"A.W. Aday, P.R. Lawler, N.R. Cook, P.M. Ridker, S. Mora, A.D. Pradhan, Lipoprotein Particle Profiles, Standard Lipids, and Peripheral Artery Disease Incidence. Circulation 138, 2330\u20132341 (2018). https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.035432","journal-title":"Circulation"},{"key":"3763_CR11","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 6, e1000097 (2009). https:\/\/doi.org\/10.1371\/journal.pmed.1000097","journal-title":"PLoS Med."},{"key":"3763_CR12","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jama.300.2.197","volume":"300","author":"FG Fowkes","year":"2008","unstructured":"Ankle Brachial Index Collaboration, F.G. Fowkes, G.D. Murray, I. Butcher, C.L. Heald, R.J. Lee, L.E. Chambless, A.R. Folsom, A.T. Hirsch, M. Dramaix, G. deBacker, J.C. Wautrecht, M. Kornitzer, A.B. Newman, M. Cushman, K. Sutton-Tyrrell, F.G. Fowkes, A.J. Lee, J.F. Price, R.B. d\u2019Agostino, J.M. Murabito, P.E. Norman, K. Jamrozik, J.D. Curb, K.H. Masaki, B.L. Rodr\u00edguez, J.M. Dekker, L.M. Bouter, R.J. Heine, G. Nijpels, C.D. Stehouwer, L. Ferrucci, M.M. McDermott, H.E. Stoffers, J.D. Hooi, J.A. Knottnerus, M. Ogren, B. Hedblad, J.C. Witteman, M.M. Breteler, M.G. Hunink, A. Hofman, M.H. Criqui, R.D. Langer, A. Fronek, W.R. Hiatt, R. Hamman, H.E. Resnick, J. Guralnik, M.M. McDermott, Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA 300, 197\u2013208 (2008). https:\/\/doi.org\/10.1001\/jama.300.2.197","journal-title":"JAMA"},{"key":"3763_CR13","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.tcm.2020.06.005","volume":"31","author":"A Mehta","year":"2021","unstructured":"A. Mehta, D.S. Dhindsa, A. Hooda, A. Nayak, C.S. Massad, B. Rao, L.F. Makue, R.R. Rajani, O. Alabi, A.A. Quyyumi, G.A. Escobar, B.J. Wells, L.S. Sperling, Premature atherosclerotic peripheral artery disease: An underrecognized and undertreated disorder with a rising global prevalence. Trends Cardiovasc. Med. 31, 351\u2013358 (2021). https:\/\/doi.org\/10.1016\/j.tcm.2020.06.005","journal-title":"Trends Cardiovasc. Med."},{"key":"3763_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2018.07.030","volume":"277","author":"YX Cao","year":"2018","unstructured":"Y.X. Cao, H.H. Liu, D. Sun, J.L. Jin, R.X. Xu, Y.L. Guo, N.Q. Wu, C.G. Zhu, S. Li, Y. Zhang, J. Sun, J.J. Li, The different relations of PCSK9 and Lp(a) to the presence and severity of atherosclerotic lesions in patients with familial hypercholesterolemia. Atherosclerosis 277, 7\u201314 (2018). https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.07.030","journal-title":"Atherosclerosis"},{"key":"3763_CR15","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.numecd.2019.06.015","volume":"29","author":"A Mattina","year":"2019","unstructured":"A. Mattina, A. Giammanco, P. Giral, D. Rosenbaum, A. Carri\u00e9, P. Cluzel, A. Redheuil, R. Bittar, S. B\u00e9liard, D. Noto, A. Quartarone, M. Averna, \u00c9. Bruckert, A. Gallo, Polyvascular subclinical atherosclerosis in familial hypercholesterolemia: The role of cholesterol burden and gender. Nutr. Metab. Cardiovasc. Dis. 29, 1068\u20131076 (2019). https:\/\/doi.org\/10.1016\/j.numecd.2019.06.015","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"3763_CR16","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1161\/ATVBAHA.117.310071","volume":"37","author":"AJ Amor","year":"2017","unstructured":"A.J. Amor, E. Ortega, V. Perea, M. Cof\u00e1n, A. Sala-Vila, I. Nu\u00f1ez, R. Gilabert, E. Ros, Relationship Between Total Serum Bilirubin Levels and Carotid and Femoral Atherosclerosis in Familial Dyslipidemia. Arterioscler Thromb. Vasc. Biol. 37, 2356\u20132363 (2017). https:\/\/doi.org\/10.1161\/ATVBAHA.117.310071","journal-title":"Arterioscler Thromb. Vasc. Biol."},{"key":"3763_CR17","doi-asserted-by":"publisher","first-page":"e1020","DOI":"10.1016\/S2214-109X(19)30255-4","volume":"7","author":"P Song","year":"2019","unstructured":"P. Song, D. Rudan, Y. Zhu, F.J.I. Fowkes, K. Rahimi, F.G.R. Fowkes, I. Rudan, Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Glob. Health 7, e1020\u2013e1030 (2019). https:\/\/doi.org\/10.1016\/S2214-109X(19)30255-4","journal-title":"Lancet Glob. Health"},{"key":"3763_CR18","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.atherosclerosis.2015.07.022","volume":"242","author":"C Pereira","year":"2015","unstructured":"C. Pereira, M.H. Miname, M.R. Makdisse, C. Watanabe, A.E. Pesaro, C.E. Jannes, R. Kalil Filho, A.C. Pereira, R.D. Santos, Peripheral arterial disease in heterozygous familial hypercholesterolemia. Atherosclerosis 242, 174\u2013178 (2015). https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.07.022","journal-title":"Atherosclerosis"},{"key":"3763_CR19","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1093\/eurjpc\/zwaa024","volume":"28","author":"LJ Mundal","year":"2022","unstructured":"L.J. Mundal, A. Hovland, J. Igland, M. Vetrhus, M.B. Veier\u00f8d, K.B. Holven, M.P. Bogsrud, G.S. Tell, T.P. Leren, K. Retterst\u00f8l, Increased risk of peripheral artery disease in persons with familial hypercholesterolaemia: a prospective registry study. Eur. J. Prev. Cardiol. 28, e11\u2013e13 (2022). https:\/\/doi.org\/10.1093\/eurjpc\/zwaa024","journal-title":"Eur. J. Prev. Cardiol."},{"key":"3763_CR20","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.jvs.2004.08.049","volume":"40","author":"EM Willigendael","year":"2004","unstructured":"E.M. Willigendael, J.A. Teijink, M.L. Bartelink, B.W. Kuiken, J. Boiten, F.L. Moll, H.R. B\u00fcller, M.H. Prins, Influence of smoking on incidence and prevalence of peripheral arterial disease. J. Vasc. Surg. 40, 1158\u20131165 (2004). https:\/\/doi.org\/10.1016\/j.jvs.2004.08.049","journal-title":"J. Vasc. Surg."},{"key":"3763_CR21","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1136\/heartjnl-2013-304082","volume":"100","author":"L Lu","year":"2014","unstructured":"L. Lu, D.F. Mackay, J.P. Pell, Meta-analysis of the association between cigarette smoking and peripheral arterial disease. Heart 100, 414\u2013423 (2014). https:\/\/doi.org\/10.1136\/heartjnl-2013-304082","journal-title":"Heart"},{"key":"3763_CR22","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.jacc.2005.09.065","volume":"47","author":"SP Marso","year":"2006","unstructured":"S.P. Marso, W.R. Hiatt, Peripheral arterial disease in patients with diabetes. J. Am. Coll. Cardiol. 47, 921\u2013929 (2006). https:\/\/doi.org\/10.1016\/j.jacc.2005.09.065","journal-title":"J. Am. Coll. Cardiol."},{"key":"3763_CR23","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.atherosclerosis.2017.01.015","volume":"257","author":"E Bruckert","year":"2017","unstructured":"E. Bruckert, O. Kalmykova, R. Bittar, V. Carreau, S. B\u00e9liard, S. Saheb, D. Rosenbaum, D. Bonnefont-Rousselot, D. Thomas, C. Emery, B. Khoshnood, A. Carri\u00e9, Long-term outcome in 53 patients with homozygous familial hypercholesterolaemia in a single centre in France. Atherosclerosis 257, 130\u2013137 (2017). https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.01.015","journal-title":"Atherosclerosis"},{"key":"3763_CR24","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/eurheartj\/ehx317","volume":"39","author":"GR Thompson","year":"2018","unstructured":"G.R. Thompson, D.J. Blom, A.D. Marais, M. Seed, G.J. Pilcher, F.J. Raal, Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol. Eur. Heart J. 39, 1162\u20131168 (2018). https:\/\/doi.org\/10.1093\/eurheartj\/ehx317","journal-title":"Eur. Heart J."},{"key":"3763_CR25","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1161\/CIRCULATIONAHA.116.024541","volume":"135","author":"L P\u00e9rez de Isla","year":"2017","unstructured":"L. P\u00e9rez de Isla, R. Alonso, N. Mata, C. Fern\u00e1ndez-P\u00e9rez, O. Mu\u00f1iz, J.L. D\u00edaz-D\u00edaz, A. Saltijeral, F. Fuentes-Jim\u00e9nez, R. de Andr\u00e9s, D. Zamb\u00f3n, M. Piedecausa, J.M. Cepeda, M. Mauri, J. Galiana, \u00c1. Brea, J.F. Sanchez Mu\u00f1oz-Torrero, T. Padr\u00f3, R. Argueso, J.P. Miramontes-Gonz\u00e1lez, L. Badim\u00f3n, R.D. Santos, G.F. Watts, P. Mata, Predicting Cardiovascular Events in Familial Hypercholesterolemia: The SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study). Circulation 135, 2133\u20132144 (2017). https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.024541","journal-title":"Circulation"},{"key":"3763_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.atherosclerosis.2020.06.011","volume":"306","author":"A Gallo","year":"2020","unstructured":"A. Gallo, S. Charriere, A. Vimont, M.J. Chapman, D. Angoulvant, F. Boccara, B. Cariou, V. Carreau, A. Carri\u00e9, E. Bruckert, S. B\u00e9liard; French REgistry of Familial hypERCHOLesterolemia (REFERCHOL) investigators, SAFEHEART risk-equation and cholesterol-year-score are powerful predictors of cardiovascular events in French patients with familial hypercholesterolemia. Atherosclerosis 306, 41\u201349 (2020). https:\/\/doi.org\/10.1016\/j.atherosclerosis.2020.06.011","journal-title":"Atherosclerosis"},{"key":"3763_CR27","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1016\/j.jcmg.2021.06.011","volume":"14","author":"A Gallo","year":"2021","unstructured":"A. Gallo, L. P\u00e9rez de Isla, S. Charri\u00e8re, A. Vimont, R. Alonso, O. Mu\u00f1iz-Grijalvo, J.L. D\u00edaz-D\u00edaz, D. Zamb\u00f3n, P. Moulin, E. Bruckert, P. Mata, S. B\u00e9liard; REFERCHOL and SAFEHEART Investigators, The Added Value of Coronary Calcium Score in Predicting Cardiovascular Events in Familial Hypercholesterolemia. JACC Cardiovasc. Imaging 14, 2414\u20132424 (2021). https:\/\/doi.org\/10.1016\/j.jcmg.2021.06.011","journal-title":"JACC Cardiovasc. Imaging"},{"key":"3763_CR28","doi-asserted-by":"publisher","unstructured":"M. Paquette, B. Cariou, S. Bernard, R.A. Hegele, A. Gallo, J. Genest, M. Trinder, L.R. Brunham, S. B\u00e9liard, A. Baass. Increased FH-Risk-Score and Diabetes Are Cardiovascular Risk Equivalents in Heterozygous Familial Hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. (2023). https:\/\/doi.org\/10.1161\/ATVBAHA.123.319957","DOI":"10.1161\/ATVBAHA.123.319957"},{"key":"3763_CR29","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1161\/CIRCULATIONAHA.118.033470","volume":"138","author":"S Beheshti","year":"2018","unstructured":"S. Beheshti, C.M. Madsen, A. Varbo, M. Benn, B.G. Nordestgaard, Relationship of Familial Hypercholesterolemia and High Low-Density Lipoprotein Cholesterol to Ischemic Stroke: Copenhagen General Population Study. Circulation 138, 578\u2013589 (2018). https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.033470","journal-title":"Circulation"},{"key":"3763_CR30","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1056\/NEJMoa061894","volume":"355","author":"P Amarenco","year":"2006","unstructured":"P. Amarenco, J. Bogousslavsky, A. Callahan 3rd, L.B. Goldstein, M. Hennerici, A.E. Rudolph, H. Sillesen, L. Simunovic, M. Szarek, K.M. Welch, J.A. Zivin, Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N. Engl. J. Med. 355, 549\u2013559 (2006). https:\/\/doi.org\/10.1056\/NEJMoa061894","journal-title":"N. Engl. J. Med."},{"key":"3763_CR31","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","volume":"380","author":"B Mihaylova","year":"2012","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaborators, B. Mihaylova, J. Emberson, L. Blackwell, A. Keech, J. Simes, E.H. Barnes, M. Voysey, A. Gray, R. Collins, C. Baigent, The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380, 581\u2013590 (2012). https:\/\/doi.org\/10.1016\/S0140-6736(12)60367-5","journal-title":"Lancet"},{"key":"3763_CR32","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/clinchem\/hvaa242","volume":"67","author":"F Emanuelsson","year":"2021","unstructured":"F. Emanuelsson, M. Benn, LDL-Cholesterol versus Glucose in Microvascular and Macrovascular Disease. Clin. Chem. 67, 167\u2013182 (2021). https:\/\/doi.org\/10.1093\/clinchem\/hvaa242","journal-title":"Clin. Chem."},{"key":"3763_CR33","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.jvs.2006.12.054","volume":"45","author":"Heart Protection Study Collaborative Group","year":"2007","unstructured":"Heart Protection Study Collaborative Group, Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J. Vasc. Surg. 45, 645\u2013654 (2007). https:\/\/doi.org\/10.1016\/j.jvs.2006.12.054","journal-title":"J. Vasc. Surg."},{"key":"3763_CR34","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","volume":"137","author":"MP Bonaca","year":"2018","unstructured":"M.P. Bonaca, P. Nault, R.P. Giugliano, A.C. Keech, A.L. Pineda, E. Kanevsky, J. Kuder, S.A. Murphy, J.W. Jukema, B.S. Lewis, L. Tokgozoglu, R. Somaratne, P.S. Sever, T.R. Pedersen, M.S. Sabatine, Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation 137, 338\u2013350 (2018). https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.032235","journal-title":"Circulation"},{"key":"3763_CR35","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1093\/eurheartj\/ehu080","volume":"35","author":"DJ Kumbhani","year":"2014","unstructured":"D.J. Kumbhani, P.G. Steg, C.P. Cannon, K.A. Eagle, S.C. Smith Jr, S. Goto, E.M. Ohman, Y. Elbez, P. Sritara, I. Baumgartner, S. Banerjee, M.A. Creager, D.L. Bhatt; REACH Registry Investigators, Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur. Heart J. 35, 2864\u20132872 (2014). https:\/\/doi.org\/10.1093\/eurheartj\/ehu080","journal-title":"Eur. Heart J."},{"key":"3763_CR36","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1161\/CIRCULATIONAHA.114.014310","volume":"131","author":"L Fern\u00e1ndez-Friera","year":"2015","unstructured":"L. Fern\u00e1ndez-Friera, J.L. Pe\u00f1alvo, A. Fern\u00e1ndez-Ortiz, B. Iba\u00f1ez, B. L\u00f3pez-Melgar, M. Laclaustra, B. Oliva, A. Mocoroa, J. Mendiguren, V. Mart\u00ednez de Vega, L. Garc\u00eda, J. Molina, J. S\u00e1nchez-Gonz\u00e1lez, G. Guzm\u00e1n, J.C. Alonso-Farto, E. Guallar, F. Civeira, H. Sillesen, S. Pocock, J.M. Ordov\u00e1s, G. Sanz, L.J. Jim\u00e9nez-Borreguero, V. Fuster, Prevalence, Vascular Distribution, and Multiterritorial Extent of Subclinical Atherosclerosis in a Middle-Aged Cohort: The PESA (Progression of Early Subclinical Atherosclerosis) Study. Circulation 131, 2104\u20132113 (2015). https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.014310","journal-title":"Circulation"},{"key":"3763_CR37","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1161\/ATVBAHA.116.307514","volume":"36","author":"L P\u00e9rez de Isla","year":"2016","unstructured":"L. P\u00e9rez de Isla, R. Alonso, N. Mata, A. Saltijeral, O. Mu\u00f1iz, P. Rubio-Marin, J.L. Diaz-Diaz, F. Fuentes, R. de Andr\u00e9s, D. Zamb\u00f3n, J. Galiana, M. Piedecausa, R. Aguado, D. Mosquera, J.I. Vidal, E. Ruiz, L. Manj\u00f3n, M. Mauri, T. Padr\u00f3, J.P. Miramontes, P. Mata; SAFEHEART Investigators, Coronary Heart Disease, Peripheral Arterial Disease, and Stroke in Familial Hypercholesterolaemia: Insights From the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study). Arterioscler Thromb. Vasc. Biol. 36, 2004\u20132010 (2016). https:\/\/doi.org\/10.1161\/ATVBAHA.116.307514","journal-title":"Arterioscler Thromb. Vasc. Biol."},{"key":"3763_CR38","doi-asserted-by":"publisher","first-page":"e025232","DOI":"10.1161\/JAHA.121.025232","volume":"11","author":"S Funabashi","year":"2022","unstructured":"S. Funabashi, Y. Kataoka, M. Hori, M. Ogura, T. Doi, T. Noguchi, M. Harada-Shiba, Characterization of Polyvascular Disease in Heterozygous Familial Hypercholesterolemia: Its Association With Circulating Lipoprotein(a) Levels. J. Am. Heart Assoc. 11, e025232 (2022). https:\/\/doi.org\/10.1161\/JAHA.121.025232","journal-title":"J. Am. Heart Assoc."},{"key":"3763_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2021.01.003","volume":"320","author":"AJ Vallejo-Vaz","year":"2021","unstructured":"A.J. Vallejo-Vaz, C.J. Packard, B.A. Ference, R.D. Santos, J.J.P. Kastelein, E.A. Stein, A.L. Catapano, T.R. Pedersen, G.F. Watts, K.K. Ray, LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial. Atherosclerosis 320, 1\u20139 (2021). https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.01.003","journal-title":"Atherosclerosis"},{"key":"3763_CR40","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1210\/jc.2018-01058","volume":"103","author":"F Emanuelsson","year":"2018","unstructured":"F. Emanuelsson, B.G. Nordestgaard, M. Benn, Familial Hypercholesterolemia and Risk of Peripheral Arterial Disease and Chronic Kidney Disease. J. Clin. Endocrinol. Metab. 103, 4491\u20134500 (2018). https:\/\/doi.org\/10.1210\/jc.2018-01058","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3763_CR41","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.3390\/jcm8071080","volume":"8","author":"L Masana","year":"2019","unstructured":"L. Masana, A. Zamora, N. Plana, M. Comas-Cuf\u00ed, M. Garcia-Gil, R. Mart\u00ed-Lluch, A. Ponjoan, L. Alves-Cabratosa, R. Elosua, J. Marrugat, I.R. D\u00e9gano, R. Ramos, Incidence of Cardiovascular Disease in Patients with Familial Hypercholesterolemia Phenotype: Analysis of 5 Years Follow-Up of Real-World Data from More than 1.5 Million Patients. J. Clin. Med 8, 1080 (2019). https:\/\/doi.org\/10.3390\/jcm8071080","journal-title":"J. Clin. Med"},{"key":"3763_CR42","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.amjcard.2017.12.040","volume":"121","author":"PA McCullough","year":"2018","unstructured":"P.A. McCullough, C.M. Ballantyne, S.K. Sanganalmath, G. Langslet, S.J. Baum, P.K. Shah, A. Koren, J. Mandel, M.H. Davidson, Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and\/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials). Am. J. Cardiol. 121, 940\u2013948 (2018). https:\/\/doi.org\/10.1016\/j.amjcard.2017.12.040","journal-title":"Am. J. Cardiol."},{"key":"3763_CR43","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.athplu.2022.03.002","volume":"48","author":"WT Fonzar","year":"2022","unstructured":"W.T. Fonzar, F.A. Fonseca, H.A. Fonseca, T.P. Silva, A.A. Rodrigues, D. Teixeira, M.E. Ishimura, M.E. Coste, C.N. Fran\u00e7a, H.T. Bianco, M. Gidlund, R.L. Morais, C.A. Bittencourt, C.A. Fonzar, V.A. Sant\u2019Anna, I.L. Maugeri, J.B. Pesquero, M.C. Izar, Atherosclerosis severity in patients with familial hypercholesterolemia: The role of T and B lymphocytes. Atheroscler 48, 27\u201336 (2022). https:\/\/doi.org\/10.1016\/j.athplu.2022.03.002","journal-title":"Atheroscler"},{"key":"3763_CR44","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.5001\/omj.2020.59","volume":"35","author":"K Al-Waili","year":"2020","unstructured":"K. Al-Waili, K. Al-Rasadi, F. Zadjali, K. Al-Hashmi, S. Al-Mukhaini, M. Al-Kindi, H. Al-Sabti, A.T. Al-Hinai, H. Farhan, I. Al-Zakwani, Clinical and Genetic Characteristics of Familial Hypercholesterolemia at Sultan Qaboos University Hospital in Oman. Oman. Med. J. 35, e141 (2020). https:\/\/doi.org\/10.5001\/omj.2020.59","journal-title":"Oman. Med. J."},{"key":"3763_CR45","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1007\/s12020-022-03013-y","volume":"76","author":"P Anagnostis","year":"2022","unstructured":"P. Anagnostis, C.V. Rizos, I. Skoumas, L. Rallidis, K. Tziomalos, E. Skalidis, V. Kotsis, M. Doumas, G. Kolovou, G. Sfikas, A. Garoufi, V. Lambadiari, I. Dima, E. Kiouri, D. Agapakis, E. Zacharis, C. Antza, V. Kolovou, C. Koumaras, G. Bantouvakis, G. Liamis, E.N. Liberopoulos, Association between lipoprotein(a) concentrations and atherosclerotic cardiovascular disease risk in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH. Endocrine 76, 324\u2013330 (2022). https:\/\/doi.org\/10.1007\/s12020-022-03013-y","journal-title":"Endocrine"},{"key":"3763_CR46","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1253\/circj.CJ-17-0392","volume":"82","author":"B Zafrir","year":"2017","unstructured":"B. Zafrir, A. Jubran, G. Lavie, D.A. Halon, M.Y. Flugelman, C. Shapira, Clinical Features and Gaps in the Management of Probable Familial Hypercholesterolemia and Cardiovascular Disease. Circ. J. 82, 218\u2013223 (2017). https:\/\/doi.org\/10.1253\/circj.CJ-17-0392","journal-title":"Circ. J."},{"key":"3763_CR47","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.atherosclerosis.2019.08.007","volume":"289","author":"PB Duell","year":"2019","unstructured":"P.B. Duell, S.S. Gidding, R.L. Andersen, T. Knickelbine, L. Anderson, E. Gianos, P. Shrader, I. Kindt, E.C. O\u2019Brien, D. McCann, L.C. Hemphill, C.D. Ahmed, S.S. Martin, J.A. Larry, Z.S. Ahmad, I.J. Kullo, J.A. Underberg, J. Guyton, P. Thompson, K. Wilemon, M.T. Roe, D.J. Rader, M. Cuchel, M.F. Linton, M.D. Shapiro, P.M. Moriarty, J.W. Knowles, Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: The CASCADE FH registry. Atherosclerosis 289, 85\u201393 (2019). https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.08.007","journal-title":"Atherosclerosis"},{"key":"3763_CR48","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.928784","volume":"27","author":"A Matta","year":"2021","unstructured":"A. Matta, V. Bongard, F. Bouisset, D. Taraszkiewicz, J.P. Rab\u00e8s, J. Ferri\u00e8res, Real-World Efficacy of Proprotein Convertase Subtilisin\/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis. Med. Sci. Monit. 27, e928784 (2021). https:\/\/doi.org\/10.12659\/MSM.928784","journal-title":"Med. Sci. Monit."},{"key":"3763_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.849008","volume":"13","author":"V Todorovova","year":"2022","unstructured":"V. Todorovova, T. Altschmiedova, M. Vrablik, R. Ceska, Familial Hypercholesterolemia: Real-World Data of 1236 Patients Attending a Czech Lipid Clinic. A Retrospective Analysis of Experience in More than 50 years. Part I: Genetics and Biochemical Parameters. Front Genet 13, 849008 (2022). https:\/\/doi.org\/10.3389\/fgene.2022.849008","journal-title":"Front Genet"},{"key":"3763_CR50","doi-asserted-by":"publisher","first-page":"168","DOI":"10.25179\/tjem.2019-65855","volume":"23","author":"TM Deneyimi","year":"2019","unstructured":"T.M. Deneyimi, Evaluation of the Frequency of Familial Hypercholesterolemia: A Single-Center Experience. Turk. J. Endocrinol. Metab. 23, 168\u2013173 (2019). https:\/\/doi.org\/10.25179\/tjem.2019-65855","journal-title":"Turk. J. Endocrinol. Metab."},{"key":"3763_CR51","doi-asserted-by":"publisher","first-page":"580","DOI":"10.5551\/jat.41483","volume":"25","author":"T Teramoto","year":"2018","unstructured":"T. Teramoto, T. Kai, A. Ozaki, B. Crawford, H. Arai, S. Yamashita, Treatment Patterns and Lipid Profile in Patients with Familial Hypercholesterolemia in Japan. J. Atheroscler. Thromb. 25, 580\u2013592 (2018). https:\/\/doi.org\/10.5551\/jat.41483","journal-title":"J. Atheroscler. Thromb."},{"key":"3763_CR52","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jacasi.2021.07.004","volume":"1","author":"S Funabashi","year":"2021","unstructured":"S. Funabashi, Y. Kataoka, M. Hori, M. Ogura, Y. Nakaoku, K. Nishimura, T. Doi, R. Nishikawa, K. Tsuda, T. Noguchi, M. Harada-Shiba, Substantially Elevated Atherosclerotic Risks in Japanese Severe Familial Hypercholesterolemia Defined by the International Atherosclerosis Society. JACC Asia 1, 245\u2013255 (2021). https:\/\/doi.org\/10.1016\/j.jacasi.2021.07.004","journal-title":"JACC Asia"},{"key":"3763_CR53","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.athplu.2022.08.001","volume":"50","author":"J Ferri\u00e8res","year":"2022","unstructured":"J. Ferri\u00e8res, M. Farnier, E. Bruckert, A. Vimont, V. Durlach, E. Ferrari, A. Gallo, F. Boccara, D. Ferri\u00e8res, S. B\u00e9liard; French FH Registry group: French REgistry of Familial hypERCHOLesterolemia (REFERCHOL), Burden of cardiovascular disease in a large contemporary cohort of patients with heterozygous familial hypercholesterolemia. Atheroscler 50, 17\u201324 (2022). https:\/\/doi.org\/10.1016\/j.athplu.2022.08.001","journal-title":"Atheroscler"},{"key":"3763_CR54","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.atherosclerosis.2019.05.017","volume":"287","author":"B Iyen","year":"2019","unstructured":"B. Iyen, N. Qureshi, J. Kai, R.K. Akyea, J. Leonardi-Bee, P. Roderick, S.E. Humphries, S. Weng, Risk of cardiovascular disease outcomes in primary care subjects with familial hypercholesterolaemia: A cohort study. Atherosclerosis 287, 8\u201315 (2019). https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.05.017","journal-title":"Atherosclerosis"},{"key":"3763_CR55","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.jacl.2017.12.014","volume":"12","author":"AM Galema-Boers","year":"2018","unstructured":"A.M. Galema-Boers, M.J. Lenzen, S.R. Engelkes, E.J. Sijbrands, J.E. Roeters van Lennep, Cardiovascular risk in patients with familial hypercholesterolemia using optimal lipid-lowering therapy. J. Clin. Lipido. 12, 409\u2013416 (2018). https:\/\/doi.org\/10.1016\/j.jacl.2017.12.014","journal-title":"J. Clin. Lipido."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-03763-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-024-03763-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-03763-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T09:32:04Z","timestamp":1720863124000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-024-03763-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,8]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["3763"],"URL":"https:\/\/doi.org\/10.1007\/s12020-024-03763-x","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,8]]},"assertion":[{"value":"21 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"M.M. worked as principal investigator in clinical trials supported by Novo Nordisk. A.G. received consulting fees or payments for lectures, presentations, manuscript writing or educational events from AMGEN, Sanofi and Regeron, Mylan, Ackea Therapeutics, Novartis, MSD, Servier, Ultragenyx. A.G. declares having received support for attending meetings and\/or travel by Amryt, Novartis, Ultragenyx and Sanofi, and participated on a data safety monitoring board or advisory board for Sanofi and Ultragenyx.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}